17508214

Source:http://linkedlifedata.com/resource/pubmed/id/17508214

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006142, umls-concept:C0013089, umls-concept:C0013216, umls-concept:C0038952, umls-concept:C0205179, umls-concept:C0220825, umls-concept:C0246415, umls-concept:C0600558, umls-concept:C0812425, umls-concept:C1514474, umls-concept:C1517927
pubmed:issue	4
pubmed:dateCreated	2008-1-9
pubmed:abstractText	The aim of the study was to identify reliable predictive biological markers for treatment outcome following neoadjuvant adriamycin/docetaxel (AT) chemotherapy in locally advanced breast cancer patients.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7806519
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic, http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Ki-67 Antigen, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone, http://linkedlifedata.com/resource/pubmed/chemical/Taxoids, http://linkedlifedata.com/resource/pubmed/chemical/docetaxel
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	0344-5704
pubmed:author	pubmed-author:ChoeY HYH, pubmed-author:EBYT MTM, pubmed-author:HanB KBK, pubmed-author:KimJ HJH, pubmed-author:LOY MYM, pubmed-author:LeeJJ, pubmed-author:LeeS HSH, pubmed-author:LimH YHY, pubmed-author:MerzFF, pubmed-author:ROYM YMY, pubmed-author:SANP DPD, pubmed-author:XuZZ, pubmed-author:YangJ HJH, pubmed-author:YipEE
pubmed:issnType	Print
pubmed:volume	61
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	569-77
pubmed:meshHeading	pubmed-meshheading:17508214-Adult, pubmed-meshheading:17508214-Aged, pubmed-meshheading:17508214-Antibiotics, Antineoplastic, pubmed-meshheading:17508214-Antineoplastic Agents, Phytogenic, pubmed-meshheading:17508214-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:17508214-Biological Markers, pubmed-meshheading:17508214-Breast Neoplasms, pubmed-meshheading:17508214-Cell Proliferation, pubmed-meshheading:17508214-Disease-Free Survival, pubmed-meshheading:17508214-Doxorubicin, pubmed-meshheading:17508214-Female, pubmed-meshheading:17508214-Genes, p53, pubmed-meshheading:17508214-Humans, pubmed-meshheading:17508214-Ki-67 Antigen, pubmed-meshheading:17508214-Middle Aged, pubmed-meshheading:17508214-Neoadjuvant Therapy, pubmed-meshheading:17508214-Prognosis, pubmed-meshheading:17508214-Prospective Studies, pubmed-meshheading:17508214-Receptors, Estrogen, pubmed-meshheading:17508214-Receptors, Progesterone, pubmed-meshheading:17508214-Survival Analysis, pubmed-meshheading:17508214-Taxoids
pubmed:year	2008
pubmed:articleTitle	Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.
pubmed:affiliation	Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong, Seoul, 135-710, South Korea.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II